StonvexLoading…
StonvexStonvexStonvexCore line items from XYL's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $2.13B | $9.04B | $6.64B | $4.37B |
Operating Income | $244.00M | $1.22B | $870.00M | $536.00M |
Net Income | $193.00M | $957.00M | $622.00M | $226.00M |
EPS (Diluted) | $0.79 | $3.92 | $2.55 | $1.62 |
Total Assets | $16.95B | $17.63B | $17.30B | $17.19B |
Total Liabilities | $5.72B | $5.88B | $5.85B | $5.88B |
Cash & Equivalents | $808.00M | $1.48B | $1.19B | $1.17B |
Free Cash Flow OCF − CapEx | $18.00M | $910.00M | $450.00M | $169.00M |
Shares Outstanding | 243.36M | 243.58M | 243.91M | 243.82M |